Showing 661-670 of 2481 results for "".
Onabotulinumtoxin in the Preventive Treatment of Chronic Migraine and Other Headaches
https://practicalneurology.com/diseases-diagnoses/headache-pain/onabotulinumtoxin-in-the-preventive-treatment-of-chronic-migraine-and-other-headaches/30833/While BoNTA shows promise in the management of chronic migraine, optimal outcomes will be acheived when clinicians learn which patients are most likely to benefit.The Health Care Debate: What Will It Mean For You?
https://practicalneurology.com/columns/practice-management/PN0909_01-php/30887/The changes proposed in Congress could mean big changes to your practice. We take a look at how things could play out.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31019/Optimizing Restless Legs Syndrome Treatment: Insights from Recent Meta-Analysis and Clinical ExperiencesA recent meta-analysis evaluating the side effects and wearing-off effects of four Restless Legs Syndrome (RLS) medications highlighted significant findings relevant to clinical practice. The stud
- Second Opinionshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0505SecondOpinion-pdf/31458/Addressing the AD-VaD Diagnostic Challenge in NeurologyIn the debate surrounding Alzheimer’s Disease (AD) versus vascular dementia (VaD) diagnosis, Dr. Geldmacher’s April 2005 article, “Diagnosing Alzheimer’s: Easy Answers vs. Right Answers,” ignited significant discourse. Dr. Geldmacher critiques c
Stroke Snapshot: Reversible Cerebral Vasoconstriction Syndrome
https://practicalneurology.com/diseases-diagnoses/stroke/stroke-snapshot-reversible-cerebral-vasoconstriction-syndrome/31820/Early correct diagnosis is imperative because RCVS presentations can overlap with diverse syndromes with disparate treatments.A Practical Approach to Selecting Patients for Amyloid-Targeting Treatments
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/a-practical-approach-to-selecting-patients-for-amyloid-targeting-treatments/36190/A review of the clinical criteria, key challenges, and future directions in selecting patients for amyloid-targeting treatments.Oral Disease Modifying Therapy for MS: Important Considerations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/oral-disease-modifying-therapy-for-ms-important-considerations/30827/The availability of an oral agent for MS may create a therapeutic dilemma for clinicians as they try to determine the role of new therapy in patient care.Monoclonal Antibodies and Migraine: What the Neurologist Needs to Know
https://practicalneurology.com/diseases-diagnoses/headache-pain/monoclonal-antibodies-and-migraine-what-the-neurologist-needs-to-know/30361/As a new age in headache medicine is set to begin, it is incumbent upon neurologists to become better familiarized with and explore the implications of monoclonal antibodies in patient care.The Approval of PFO Closure in the United States
https://practicalneurology.com/diseases-diagnoses/stroke/the-approval-of-pfo-closure-in-the-united-states/30295/A look back at the long road to FDA approval and the implications on patient care options going forward.Update on Treatment Options for Dementia
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/update-on-treatment-options-for-dementia/30528/Although there is no treatment to correct the pathological process that leads to AD, there is a large window of opportunity to treat this condition before it becomes clinically evident.